Soooo … I heard Silicon Valley billionaire Peter Thiel, age 48, is using the blood of twentysomethings to stay young.
Actually, he's not doing that yet. Reportedly, he's considered receiving blood transfusions from younger people, which he hopes might reverse signs of aging, but he hasn't actually said anything publicly beyond hint that he might be game.
Wait, is that even possible? Sucking in young blood to make yourself younger?
Let's back up a few steps. There's been some exciting, preliminary research in mice that suggests there's something about young blood. In these experiments, scientists have stitched together a young mouse and old mouse so that their circulatory systems are pumping the same blood through each other's veins. This makes tissue stronger in the older mice: repairs spinal cord damage, prompts new brain cells to grow, and “even makes their fur shinier,” writes journalist Megan Scudellari for Nature in a great primer on the research's history.
When these experiments were done in the 1950s, mice sometimes reacted by trying to bite each other's heads off. It was not great. But in modern experiments, they are carefully selected for compatibility and hang out beforehand, which seems to help. They seem to behave normally while sewn together and can even be separated afterward. The older mice might be healthier for it but as Scudellari writes, “no one has convincingly shown that young blood lengthens lives, and there is no promise that it will.”
You'd have to be physically stitched to another person and receiving their blood for this to work?
No, no, obviously not, though that is the method that's shown most of the best results in mice. There's some evidence that repeated injections of plasma will work the same way, too: A 2014 study showed that they improved cognitive function in aging mice. But we would not stitch humans together, no.
Well, what are we doing to humans then?
We're basically trying to figure out if any of this translates to humans. This is all very preliminary, but there are actually a couple companies trying out various methods of the idea that young blood can reduce disease in older patients. Stanford researcher Tony Wyss-Coray, who has long been stitching together mice, founded a company called Alkahest and is carrying out a clinical trial on 18 people with Alzheimer's to see if plasma injections can improve their cognitive function—and, if so, which parts of the plasma are doing the work. The general understanding is that the proteins in young blood have some sort of restorative property, though no one quite understands the mechanism that makes young blood useful.
Another company, Ambrosia LLC, founded by a recently minted Stanford MD, is booting up a clinical trial for anyone over 35 who is aging (aka anyone over the age of 35). (It's this company that attracted the attention of Thiel's health adviser, though there's no sign that Thiel himself has enrolled in the trial.)
In the Ambrosia trial, 600 participants will each receive a liter-and-a-half of blood from someone under 25 over the course of a couple days. Before and after the trial, Ambrosia will analyze various measurements of the participants' health to see if they can assess any change from the infusion.
Where do they get the young blood?
They buy it from blood banks, just like any other hospital would.
OK, I guess that's not that weird. So, I'd like to live longer. How do I sign up?
Whoa, slow down. This will probably not actually extend people's lives. It's not even always effective in mice. In a trial that involved injecting rodents with plasma over the course of 16 weeks, the mice didn't live any longer than a control group injected with saline. There isn't enough research done in humans to know if the small benefits to tissue health transfers, and we do know that mice are not perfect foils for the human body.
“There's just no clinical evidence [that the treatment will be beneficial], and you're basically abusing people's trust and the public excitement around this,” Wyss-Coray told Science magazine of the Ambrosia trial. (Yes, his company could be considered a competitor to Ambrosia, though it doesn't seem like he's selling anything yet.)
Ambrosia's founder Jesse Karmazin, on the other hand, tells me that he finds the evidence from mouse studies along with encouraging results from the few small studies that have been conducted in humans, like Wyss-Coray's, enough to justify his trial.
At any rate, transfusions are very safe when properly supervised, so it's not like he's trying some experimental procedure that could do harm. He is, however, charging participants $8,000.
Seems pretty fair for a shot at longer life, no?
Well, normally, in clinical trials, people are paid for their time and participation, not the other way around. This is actually pretty weird. So weird, in fact, that it's unlikely this trial will result in reputable results able to tell us anything meaningful about blood transfusions.
Taking money from participants is referred to as pay-to-play. While a handful of researchers are trying it, it's rife with ethical issues, many of which University of Pennsylvania medical ethicist Ezekiel J. Emanuel (and co-authors) outlined in an editorial for Science Translational Medicine last year. (They also noted that the method has been favored by “unscrupulous companies and health facilities” looking to turn a profit.)
The reason why this is suspect is because clinical trials are setup to test a treatment as objectively as possible. In fact, the highest standard of clinical trial is one that is placebo-controlled and conducted double-blind. Participants are recruited based on specific criteria—for example, if they all have a disease and are within a certain age range. These participants are randomly assigned to different groups. One of these groups receives a placebo (a sugar pill instead of a drug), so researchers can understand what changes are attributable to the drug itself and what changes are attributable to the theater of the treatment. Patients are put in these groups randomly: Ideally, neither the patient nor the experimenter knows what kind of treatment they're receiving.
Isn't Ambrosia doing that?
Nope. In Ambrosia's trial, all patients appear to be getting the same treatment—there is no placebo set up, so there is nothing to blind. The thinking is that people shelling out eight grand won't accept the terms of a randomized treatment, and the possibility of receiving a mere placebo—the very backbone of a good clinical trial.
The terms of enrollment for Ambrosia's trial are also laughably general. I mean, 35-year-olds aren't exactly elderly. They aren't going to have any diseases associated with aging. As Harvard researcher Amy Wagers told Scudellari in Nature last year, most effective use of young blood will probably be for treating a specific disease, or helping elderly recover from surgery. It's hard to know what kind of measurable effect it might have on a—by all appearances spry—40-something like Thiel.
It also means that Ambrosia's sample is going to be skewed toward people who are can afford the treatment and who self-select to prioritize youth. There's no telling how this sample size may compare to the average person.
Maybe it's not a perfect clinical trial. But won't the people still get something out of it?
Honestly, who knows! The pay-to-play model is potentially very dishonest: Most clinical trials do not work out. This is how science goes. A clinical trial is an experiment, not a service. When scientists set it up like one, it puts patients in a position to be taken advantage of because the treatment being tested probably will not work.
Hmmm. But this is legal and everything?
Yes, technically it is. Blood transfusions are a common, Food and Drug Administrationapproved treatment, and Karmazin has a medical degree, so he can administer them at his discretion.
I asked Karmazin about some criticisms of the pay-to-play model. He wrote in an email that “patients frequently pay for off-label uses of medications, based on physician judgment.” That's true. But the doctor's judgement in this case is rather optimistic. The price is also pretty steep.
I think I'm going to sit this one out and see what they come up with.
That seems best.
What else I can do to live longer?
There are a number of actions you can take that have been shown to extend lifespan, such as eating more vegetables, exercising regularly, or not smoking.
Yeah, yeah, I know.
Joe.Gibson posted a photo:
Part of a project I have set myself to upload a photo for each day for the two weeks that I am off work.
Went to try and catch some shots of the sunset from Royal Hill in Greenwich.
crissudi posted a photo:
crissudi posted a photo:
crissudi posted a photo:
crissudi posted a photo:
crissudi posted a photo:
crissudi posted a photo:
www.matthewcattellphotography.com posted a photo:
A Red Deer Stag in a misty meadow, photographed so that the low morning sun created a halo around its velvet-covered antlers.
Euro airliner firm Airbus is sponsoring a glider capable of soaring to greater altitudes than the famous SR-71 Blackbird spy aircraft.…
Full Text:
We learn a lot about objects by manipulating them: poking, pushing, prodding, and then seeing how they react. We obviously can't do that with videos — just try touching that cat video on your phone and see what happens. But is it crazy to think that we could take that video and simulate how the cat moves, without ever interacting with the real one? Researchers from MIT's Computer Science and Artificial Intelligence Laboratory have recently done just that, developing an imaging technique called Interactive Dynamic Video (IDV) that lets you reach in and “touch” objects in videos. Using traditional cameras and algorithms, IDV looks at the tiny, almost invisible vibrations of an object to create video simulations that users can virtually interact with.
Image credit: Abe Davis/MIT CSAIL
Full Text:
The Yellowstone River in Yellowstone National Park after a late spring snowstorm. Earlier annual snowmelt periods may decrease streamflow and reduce forests' ability to regulate atmospheric carbon dioxide, according to a new study. By mid-century, a shift in snowmelt timing could lead to 45 percent reduction of forest CO2 uptake.
Image credit: Theodore Barnhart
When an earnest undergraduate quizzed the aged E M Forster about the good life, the novelist is supposed to have replied: “Don't ask about the good life. Find out what you enjoy.” I'm not sure of the source of the story, which I've heard in more than one version, but the dictum attributed to the novelist encapsulates a popular type of liberal philosophy. Arguments about the good are unending and inconclusive. Despite Aristotle, Buddha, Laozi and all those who followed them, there is no more agreement on the subject than there was two and a half millennia ago. Given the essential elusiveness of goodness, why not focus on something we can judge with reasonable confidence? After all, we all know what we like. If we stick to what we enjoy, we can hardly go wrong.
The trouble is that, in fact, what we like is often unclear to us. As Tom Vanderbilt writes:
Related: The secret of taste: why we like what we like | Tom Vanderbilt
Continue reading..."I think the Bayindir finds are Phrygian."
"This is a fabulous discovery. I have never seen anything like it. Each and every piece is of purely Phrygian type."
"Thanks Suzan. I've written about this with Keith DeVries in 2012, and we still stand by that."
"Dear Suzan, you may consult the catalog entry of the exhibition Assyria to Iberia, at the Dawn of the Classical Age, edited by Joan Aruz, Sarah B. Graff and Yelena Rakic, New York, 2014, p. 308, nr. 180 with previous references as well as the attached article on the same subject. Should you need any further help, do not hesitate to contact me.
Athanasia"
"Initially attributed to a Greek artist under strong Near Eastern influence, more recently the figurine has been convincingly suggested to have originated from a Phrygian workshop. It has also been proposed that this unique object was made as a decorative attachment for the magnificent throne of Midas. . . ."
"Although it could be argued that stylistic analysis is in the end largely subjective, even a cursory look at the items compared shows no components of the Delphi figure's face (mouth, eyes, etc.) or hair reflect Phrygian features."
"The ivory piece from Delphi, currently on display at the University Museum in Philadelphia, is assuredly not Phrygian [emphasis added], in my opinion, but the product of a west Anatolian or East Greek workshop. The meander is found in Phrygian furniture, but it came to be such a widely used motif that one cannot use it to determine origin. It is a strange piece that I have wondered about for years. The lion, for whatever reason has an erection, for which I know of no parallels."
"That is not an erection!"
"Have you read Brian Rose's 2012 article in The Archaeology of Phrygian Gordion? His comparanda is not convincing[emphasis added], and it is generally acknowledged by colleagues that there is no evidence [emphasis added] that the ivory Lion Tamer statuette is Phrygian in style per se.
The Delphi Museum's posted description [you emailed me] is much more accurate than Rose's contention. Do you know if the Delphi Museum post is official? Is this what the museum label for the Lion Tamer says? Can you please let me know? I am curious.
In terms of the meander design on the base (which is published upside down in Rose's article), this exact pattern is not found on any Phrygian furniture that I know of, and the cross-within-a-square is particularly unusual in that regard.
In terms of form and joinery, the piece was recovered in fragments and has been restored; not all of it is preserved, and I have not seen the bottom of the base. There is a mortise (square cutting) in the back of the figure, but it is shallow, suggesting that the Lion Tamer was not a structural element but decorative. I am not sure how or where the Lion Tamer would have been attached to whatever it once belonged to.
Apart from the style of the ivory figure, the pattern on the base, and its form and joinery, however, one must consider whether the Lion Tamer is from a piece of Phrygian furniture at all -- and whether there is any evidence that it "is" or "may be" from Midas's famous throne.
1. First, a large collection of Phrygian royal furniture survives from the tombs at Gordion, and none of it has carved figures as elements, let alone ivory figures of this sort. You can see what the Gordion furniture looks like from my publications, particularly my 2010 Brill book on the furniture from Tumulus MM (in the MMA library, the Bard Graduate Center library, and elsewhere). A brief summary and bibliography can be found in the Wikipedia article:
https://en.wikipedia.org/wiki/Gordion_Furniture_and_Wooden_Artifacts
Although there are no "thrones" from the Gordion tombs, there was a small chair in Tumulus MM, but it has no carved human figures -- only a crest with small animals in panels carved in relief.
There were ancient Near Eastern thrones that had carved human figures (or deities) as elements, but there is no evidence of this from Phrygia. Such figural elements occur initially in the third millennium B.C., and they are found later in Assyria, Urartu, and elsewhere in the first millennium B.C.
Ivory attachments of various types are well known from the second and first millennia in the ANE [Ancient Near East], but ivory attachments are not found on the royal furniture from the Gordion tombs. Several small, square ivory plaques were excavated in association with wood fragments from Megaron 3 on the City Mound at Gordion, but the figures carved in relief on these plaques are Phrygian in style, like those on the crest rail of the chair from Tumulus MM -- and bear no stylistic resemblance to the Lion Tamer from Delphi. You can read about ANE furniture in my article, "Furniture in Ancient Western Asia," here attached.
Rather, the design and decoration of Phrygian royal furniture involved the abstraction of three-dimensional forms, and elaborate inlaid geometric patterns with complex symmetry, including mazes, apotropaic and religious symbols, and "genealogical patterns." Phrygian furniture seems to be completely different from its eastern counterparts. The examples we have are made of wood, typically boxwood inlaid with juniper and walnut, which survived in relatively good condition in several tombs at Gordion.
So, the ivory Lion Tamer is in no way characteristic of Phrygian furniture, in terms of extant evidence. In fact, it looks completely unrelated in this regard.
2. Second, might the Lion Tamer have come from the throne that Midas dedicated in the sanctuary of Apollo at Delphi? Although I suppose it is remotely possible, there is absolutely no evidence for this contention. As already discussed, there is no evidence that the statuette is actually Phrygian, although it may have been made somewhere in Anatolia. And carved figures of this type are not found on Phrygian royal furniture as we know it.
But let's just imagine that Midas did have a throne with carved figures on it. Maybe he imported it from Urartu or Assyria. Even if that were the case, there is no evidence that this particular carved figure came from it [emphasis in original]. Indeed, the Lion Tamer does not look either Assyrian or Urartian, and it is hard to tell exactly where it was made or what it was once attached to.
I do not doubt that Herodotus saw a throne at Delphi that he believed was dedicated by King Midas [Herodotus 1.14). Unfortunately, he does not describe it.
I gave a lecture on April 2, 2016, at the Penn Museum at the conference, "The World of Phrygian Gordion," in which I said all these things. Brian Rose was in attendance, as the convener of the conference. He heard what I said and appeared to acknowledge the cogency of my argument. Nonetheless he continues to stand by his 2012 article.
Oscar[Muscarella]'s source article on the Lion Tamer is very good on the various issues. I also plan to write an article on "Midas's Throne," as it is important that Rose's article not stand unchallenged."
-- This feed and its contents are the property of The Huffington Post, and use is subject to our terms. It may be used for personal consumption, but may not be distributed on a website.
Looking for a healthy variety of bugs? You might want to try searching in your wealthiest friend's house. Neighborhood income is a good predictor of the number of kinds of bugs in homes.
Nighttime driving restrictions on teens may save lives, a study finds, but should probably be shifted to include late evening. A third of all fatal crashes with teen drivers happen after dark.
www.matthewcattellphotography.com posted a photo:
A Red Deer Stag in a misty meadow, photographed so that the low morning sun created a halo around its velvet-covered antlers.
brady tuckett posted a photo:
Pentacon 30mm f/3.5
The Collecting Traveler posted a photo:
The Collecting Traveler posted a photo: